Propel

 

About Propel Treatment

          Sinusitis 

PROPEL is clinically proven to improve surgical outcomes for chronic sinusitis sufferers.

When placed in the sinus following surgery, PROPEL decreases scarring and inflammation,
reducing the need for additional surgical procedures as well as  oral steroids and their
potential side effects1.

The spring-like PROPEL implant props open the ethmoid sinus to maintain the surgical opening,
delivers an anti-inflammatory medication directly to the sinus lining, and then dissolves, avoiding
the need for removal.  Talk with your doctor to see if PROPEL is the right option for you.

 

Healthy Sinuses    Diseased Sinuses

       Healthy Sinuses                                                                     Diseased Sinuses

 

Chronic Sinusitis: One of America's Most Common Health Conditions

               31 million people are afflicted with chronic sinusitis each year, making it one of the most common health conditions in the United States2.

        The sinuses are air-filled cavities located within the bones around the nose and eyes that allow for natural ventilation and drainage.  In Chronic Sinusitis, the sinus linings become inflamed, blocking the natural drainage passageways and leading to chronic infections and nasal obstruction.

Patients with chronic sinusitis often suffer from debilitating symptoms such as facial pain or pressure, nasal congestion and difficulty breathing, discolored nasal discharge, loss of smell and taste, headache, fatigue and depression.

 

A Need to Improve Treatment Outcomes

Chronic sinustis often requires a complex combination of surgical and medical treatments.  When sinusitis does not respond to medications, surgery to enlarge the openings that drain the sinuses may be an option. 

Each year, 500,000 patients undergo ehtmoid sinus surgery to treat the condition3.  Although sinus surgery is effective, the majority of patients experience recurrent symptoms within the first year; as many as 25 percent then undergo revision surgery due to recurrent obstruction of the sinus cavity4.

Propel

Chronic Sinusitis Patient Have A New Weapon - Propel

The goal of surgical treatment for chronic sinusitis is to enlarge the inflamed or obstructed sinus passageways.  Post-surgery check-ups are required to inspect the sinus cavities to monitor for inflammation and scarring and treat accordingly with surgery and/or oral steroids.

The dissolvable PROPEL Steroid-Releasing Implant is the first in a new category of products offering localized, controlled delivery of steroid directly to the sinus tissue to maintain the openings created in surgery.

Applying principles of coronary drug-eluting stends to sinusitis sufferers, the spring-like implants gradually deliver an advanced steroid with anti-inflammatory properties (mometasone furoate) directly to the sinus lining, then dissolve into the body following endoscopic sinus surgery.  The result is improved surgical outcomes, reducing the need for additional surgical procedures and for sustemic steroids, which can have serious side effects.

Three rigorous clinical trials5 have demonstrated that the implant is safe and maintains the results of sinus surgery by propping open the sinus cavities and decreasing post-operative scarring and inflammation.  Reducing these factors is proven to improve long-term outcomes6 and to reduce the need for repeat surgery and oral steroids, which can have serious side effects.  PROPEL is the only product used in sinus surgery to be supported by level 1-A evidence. 

 

________________________________________________________________________________________.

1 Han JK, Marple BF, Smith TL et al. IFAR.2012;2:271-279

2 National Health Interview Survey 2006.  CDC National Center for Health Statistics.  Series 10 Number 235.

3 Schaitkin BM, May M, Shapiro A: et al,. Laryngoscope.  1993;103: 1117-20

4 Pilot study results: Murr AH, Smith TL, Hwang PH, et al. IFAR.  2011;1:23-32.; ADVANCE II Clinical trial:  Marple BF, Smith TL, Han JK et al.  Otolaryngol Head Neck Surg.2012; 146(6) 1004-1011.; Meta-analysis: Han JK, Marple BF, Smith TL et al IFAR.  2012; 2:271-279.

5 Kennedy DW, Wright ED, Goldberg AN. Laryngoscope.  2000;110:29-31.

 

 1 1sdfs

 

____________________________----------------hbhaedfk